Juvéderm Voluma XC
Allergan Aesthetics, an AbbVie company
cheeks, chin, temples
Juvéderm Voluma vs. Restylane Kysse
Last verified 7/30/2026
Restylane Kysse
Galderma / Q-Med AB
lips, upper perioral lines
Quick comparison
| Attribute | Juvéderm Voluma XC | Restylane Kysse |
|---|---|---|
| Manufacturer | Allergan Aesthetics, an AbbVie company | Galderma / Q-Med AB |
| Base material | cross-linked hyaluronic acid gel with lidocaine | cross-linked hyaluronic acid gel with lidocaine |
| Intended areas | cheeks, chin, temples | lips, upper perioral lines |
| Primary purpose | Deep augmentation for age-related midface volume deficit, chin-profile improvement, and temple hollowing in adults over 21 under the current US labelling. | Add fullness to the lips and correct upper perioral rhytids in adults over 21. |
| Product behavior | A 20 mg/mL cross-linked hyaluronic acid gel with 0.3% lidocaine is implanted in product-specific deep tissue planes to add volume and contour. | Cross-linked hyaluronic acid gel with lidocaine is injected into lip or upper-perioral tissue to add temporary volume and smooth selected lines. |
| Results timing | Volume change is immediate; touch-up assessment in pivotal studies occurred after early swelling, commonly at weeks rather than the same day. | Volume is visible immediately; assessment should allow early lip swelling to settle. |
| Typical longevity | Cheek clinical-study benefit was evaluated through up to 24 months; this is not a promise that every treatment or newly approved area lasts 24 months. | In the FDA pivotal study, 60% of subjects were responders at week 48; this does not guarantee one-year correction for every patient. |
| Downtime and swelling | Common; severity and duration vary by area and technique. | Very common after lip injection; most trial diary symptoms resolved within about two weeks. |
| Reversibility | May often be reduced with off-label hyaluronidase, but complete or immediate reversal is not guaranteed. | May often be reduced with off-label hyaluronidase, but response is variable and complete reversal is not guaranteed. |
| Pricing basis | Usually per 1 mL syringe; total cost depends on area and number of syringes. | Usually per 1 mL syringe; half-syringe or promotional pricing must remain separate. |
| Regulatory status | FDA-approved by PMA supplements for cheek augmentation for age-related midface volume deficit, chin augmentation, and temple hollowing in adults over 21. | FDA-approved under PMA supplement P140029/S021 for lip augmentation and correction of upper perioral rhytids in patients over 21. |
| Major limitations | Using a structural cheek/chin/temple filler for a lip goal is an intended-area mismatch; one syringe may also be insufficient for bilateral structural correction. | Swelling can temporarily exaggerate the result, and the product is not designed to replace structural cheek or chin augmentation. |
Manufacturer
- Juvéderm Voluma XC
- Allergan Aesthetics, an AbbVie company
- Restylane Kysse
- Galderma / Q-Med AB
Base material
- Juvéderm Voluma XC
- cross-linked hyaluronic acid gel with lidocaine
- Restylane Kysse
- cross-linked hyaluronic acid gel with lidocaine
Intended areas
- Juvéderm Voluma XC
- cheeks, chin, temples
- Restylane Kysse
- lips, upper perioral lines
Primary purpose
- Juvéderm Voluma XC
- Deep augmentation for age-related midface volume deficit, chin-profile improvement, and temple hollowing in adults over 21 under the current US labelling.
- Restylane Kysse
- Add fullness to the lips and correct upper perioral rhytids in adults over 21.
Product behavior
- Juvéderm Voluma XC
- A 20 mg/mL cross-linked hyaluronic acid gel with 0.3% lidocaine is implanted in product-specific deep tissue planes to add volume and contour.
- Restylane Kysse
- Cross-linked hyaluronic acid gel with lidocaine is injected into lip or upper-perioral tissue to add temporary volume and smooth selected lines.
Results timing
- Juvéderm Voluma XC
- Volume change is immediate; touch-up assessment in pivotal studies occurred after early swelling, commonly at weeks rather than the same day.
- Restylane Kysse
- Volume is visible immediately; assessment should allow early lip swelling to settle.
Typical longevity
- Juvéderm Voluma XC
- Cheek clinical-study benefit was evaluated through up to 24 months; this is not a promise that every treatment or newly approved area lasts 24 months.
- Restylane Kysse
- In the FDA pivotal study, 60% of subjects were responders at week 48; this does not guarantee one-year correction for every patient.
Downtime and swelling
- Juvéderm Voluma XC
- Common; severity and duration vary by area and technique.
- Restylane Kysse
- Very common after lip injection; most trial diary symptoms resolved within about two weeks.
Reversibility
- Juvéderm Voluma XC
- May often be reduced with off-label hyaluronidase, but complete or immediate reversal is not guaranteed.
- Restylane Kysse
- May often be reduced with off-label hyaluronidase, but response is variable and complete reversal is not guaranteed.
Pricing basis
- Juvéderm Voluma XC
- Usually per 1 mL syringe; total cost depends on area and number of syringes.
- Restylane Kysse
- Usually per 1 mL syringe; half-syringe or promotional pricing must remain separate.
Regulatory status
- Juvéderm Voluma XC
- FDA-approved by PMA supplements for cheek augmentation for age-related midface volume deficit, chin augmentation, and temple hollowing in adults over 21.
- Restylane Kysse
- FDA-approved under PMA supplement P140029/S021 for lip augmentation and correction of upper perioral rhytids in patients over 21.
Major limitations
- Juvéderm Voluma XC
- Using a structural cheek/chin/temple filler for a lip goal is an intended-area mismatch; one syringe may also be insufficient for bilateral structural correction.
- Restylane Kysse
- Swelling can temporarily exaggerate the result, and the product is not designed to replace structural cheek or chin augmentation.
Benefits and trade-offs
Juvéderm Voluma XC
- Midface volume, cheek contour, chin projection, or temple hollowing when used in the corresponding labelled plane.
- It is not a lip-specific filler, does not relax facial muscles, and does not tighten skin directly.
- Using a structural cheek/chin/temple filler for a lip goal is an intended-area mismatch; one syringe may also be insufficient for bilateral structural correction.
Restylane Kysse
- Lip fullness, definition, and selected upper-lip lines.
- It is not intended in this profile for cheek, chin, or temple structural augmentation and does not relax muscles.
- Swelling can temporarily exaggerate the result, and the product is not designed to replace structural cheek or chin augmentation.
Details
Open a section for more context. Sources appear beside the claims they support.
Placement and effect
| Attribute | Juvéderm Voluma XC | Restylane Kysse |
|---|---|---|
| What it is generally used for | Deep augmentation for age-related midface volume deficit, chin-profile improvement, and temple hollowing in adults over 21 under the current US labelling.
| Add fullness to the lips and correct upper perioral rhytids in adults over 21.
|
| Adds volume | Yes
| Yes
|
| Expected result magnitude | Structural, area-dependent contour change rather than fine surface-line smoothing.
| Localized lip and upper-perioral correction.
|
| What it primarily changes | Midface volume, cheek contour, chin projection, or temple hollowing when used in the corresponding labelled plane.
| Lip fullness, definition, and selected upper-lip lines.
|
What it is generally used for
- Juvéderm Voluma XC
- Deep augmentation for age-related midface volume deficit, chin-profile improvement, and temple hollowing in adults over 21 under the current US labelling.
- Juvéderm Voluma XC Instructions for Use, P110033/S070 · accessdata.fda.gov
- Restylane Kysse
- Add fullness to the lips and correct upper perioral rhytids in adults over 21.
- Restylane Kysse Instructions for Use · restylaneusa.com
Adds volume
Expected result magnitude
- Juvéderm Voluma XC
- Structural, area-dependent contour change rather than fine surface-line smoothing.
- Juvéderm Voluma XC Instructions for Use, P110033/S070 · accessdata.fda.gov
- Restylane Kysse
- Localized lip and upper-perioral correction.
- Restylane Kysse Instructions for Use · restylaneusa.com
What it primarily changes
- Juvéderm Voluma XC
- Midface volume, cheek contour, chin projection, or temple hollowing when used in the corresponding labelled plane.
- Juvéderm Voluma XC Instructions for Use, P110033/S070 · accessdata.fda.gov
- Restylane Kysse
- Lip fullness, definition, and selected upper-lip lines.
- Restylane Kysse Instructions for Use · restylaneusa.com
Treatment experience
| Attribute | Juvéderm Voluma XC | Restylane Kysse |
|---|---|---|
| Downtime | Injection-site responses are common and may last days to weeks.
| Lip-site reactions are very common; swelling, tenderness, bruising, lumps, and firmness may remain visible for days and sometimes longer.
|
| Swelling | Common; severity and duration vary by area and technique.
| Very common after lip injection; most trial diary symptoms resolved within about two weeks.
|
| Bruising | Common after injection.
| Common after lip injection.
|
Downtime
- Juvéderm Voluma XC
- Injection-site responses are common and may last days to weeks.
- Juvéderm Voluma XC Instructions for Use, P110033/S070 · accessdata.fda.gov
- Restylane Kysse
- Lip-site reactions are very common; swelling, tenderness, bruising, lumps, and firmness may remain visible for days and sometimes longer.
- Restylane Kysse Patient Safety Information · restylaneusa.com
Swelling
- Juvéderm Voluma XC
- Common; severity and duration vary by area and technique.
- Juvéderm Voluma XC Instructions for Use, P110033/S070 · accessdata.fda.gov
- Restylane Kysse
- Very common after lip injection; most trial diary symptoms resolved within about two weeks.
- Restylane Kysse Patient Safety Information · restylaneusa.com
Bruising
- Juvéderm Voluma XC
- Common after injection.
- Juvéderm Voluma XC Instructions for Use, P110033/S070 · accessdata.fda.gov
- Restylane Kysse
- Common after lip injection.
- Restylane Kysse Patient Safety Information · restylaneusa.com
Risks and limitations
| Attribute | Juvéderm Voluma XC | Restylane Kysse |
|---|---|---|
| Documented risks | Swelling, tenderness, firmness, lumps, bruising, redness, infection, inflammatory reactions, and rare intravascular injection with necrosis, visual impairment, or stroke.
| Swelling, bruising, tenderness, pain, lumps, infection, inflammatory reactions, and rare intravascular injection with necrosis, vision impairment, or stroke.
|
| Most likely disappointment | Using a structural cheek/chin/temple filler for a lip goal is an intended-area mismatch; one syringe may also be insufficient for bilateral structural correction.
| Swelling can temporarily exaggerate the result, and the product is not designed to replace structural cheek or chin augmentation.
|
| When this treatment may not be appropriate | Not appropriate for lip augmentation under this profile or when filler contraindications, infection, severe allergy history, or a non-volume concern applies.
| Not appropriate for the Voluma-profile cheek, chin, or temple goals; avoid when label contraindications or active infection apply.
|
| Provider-dependent variables | Area-specific plane, amount, facial proportions, injection technique, and vascular anatomy.
| Lip anatomy, amount, symmetry, injection plane, technique, and management of vascular compromise.
|
| Skin-tone considerations | The US labelling reports study enrollment across Fitzpatrick skin types; this does not eliminate individual risk of bruising, inflammation, or pigment change.
| The pivotal study included a Fitzpatrick-skin-type subgroup analysis; individual bruising and pigment response can still vary.
|
Documented risks
- Juvéderm Voluma XC
- Swelling, tenderness, firmness, lumps, bruising, redness, infection, inflammatory reactions, and rare intravascular injection with necrosis, visual impairment, or stroke.
- Juvéderm Voluma XC Instructions for Use, P110033/S070 · accessdata.fda.gov
- Restylane Kysse
- Swelling, bruising, tenderness, pain, lumps, infection, inflammatory reactions, and rare intravascular injection with necrosis, vision impairment, or stroke.
- Restylane Kysse Patient Safety Information · restylaneusa.com
Most likely disappointment
- Juvéderm Voluma XC
- Using a structural cheek/chin/temple filler for a lip goal is an intended-area mismatch; one syringe may also be insufficient for bilateral structural correction.
- Juvéderm Voluma XC Instructions for Use, P110033/S070 · accessdata.fda.gov
- Restylane Kysse
- Swelling can temporarily exaggerate the result, and the product is not designed to replace structural cheek or chin augmentation.
- Restylane Kysse Instructions for Use · restylaneusa.com
When this treatment may not be appropriate
- Juvéderm Voluma XC
- Not appropriate for lip augmentation under this profile or when filler contraindications, infection, severe allergy history, or a non-volume concern applies.
- Juvéderm Voluma XC Instructions for Use, P110033/S070 · accessdata.fda.gov
- Restylane Kysse
- Not appropriate for the Voluma-profile cheek, chin, or temple goals; avoid when label contraindications or active infection apply.
- Restylane Kysse Patient Safety Information · restylaneusa.com
Provider-dependent variables
- Juvéderm Voluma XC
- Area-specific plane, amount, facial proportions, injection technique, and vascular anatomy.
- Juvéderm Voluma XC Instructions for Use, P110033/S070 · accessdata.fda.gov
- Restylane Kysse
- Lip anatomy, amount, symmetry, injection plane, technique, and management of vascular compromise.
- Restylane Kysse Patient Safety Information · restylaneusa.com
Skin-tone considerations
- Juvéderm Voluma XC
- The US labelling reports study enrollment across Fitzpatrick skin types; this does not eliminate individual risk of bruising, inflammation, or pigment change.
- Juvéderm Voluma XC Instructions for Use, P110033/S070 · accessdata.fda.gov
- Restylane Kysse
- The pivotal study included a Fitzpatrick-skin-type subgroup analysis; individual bruising and pigment response can still vary.
- Restylane Kysse Patient Safety Information · restylaneusa.com
Evidence and regulatory status
| Attribute | Juvéderm Voluma XC | Restylane Kysse |
|---|---|---|
| United States regulatory status | FDA-approved by PMA supplements for cheek augmentation for age-related midface volume deficit, chin augmentation, and temple hollowing in adults over 21.
| FDA-approved under PMA supplement P140029/S021 for lip augmentation and correction of upper perioral rhytids in patients over 21.
|
| Canadian regulatory status | Health Canada MDALL lists Juvéderm Voluma with lidocaine under active Class III medical-device licence 77899.
| Health Canada MDALL lists Restylane Kysse under active Class III licence 95283.
|
| Evidence status | High for formulation, labelled areas, contraindications, adverse events, and pivotal-study follow-up; individual durability and required volume vary.
| High for formulation, labelled area, pivotal-study outcomes, and safety; long-term response remains individual.
|
United States regulatory status
- Juvéderm Voluma XC
- FDA-approved by PMA supplements for cheek augmentation for age-related midface volume deficit, chin augmentation, and temple hollowing in adults over 21.
- JUVÉDERM VOLUMA XC summary of safety and effectiveness · accessdata.fda.gov
- FDA PMA P110033/S070 · accessdata.fda.gov
- Restylane Kysse
- FDA-approved under PMA supplement P140029/S021 for lip augmentation and correction of upper perioral rhytids in patients over 21.
- FDA PMA P140029/S021 · accessdata.fda.gov
Canadian regulatory status
- Juvéderm Voluma XC
- Health Canada MDALL lists Juvéderm Voluma with lidocaine under active Class III medical-device licence 77899.
- Health Canada MDALL: Allergan Juvéderm licences · health-products.canada.ca
- Restylane Kysse
- Health Canada MDALL lists Restylane Kysse under active Class III licence 95283.
- Health Canada MDALL: Q-Med Restylane licences · health-products.canada.ca
Evidence status
- Juvéderm Voluma XC
- High for formulation, labelled areas, contraindications, adverse events, and pivotal-study follow-up; individual durability and required volume vary.
- FDA PMA P110033/S070 · accessdata.fda.gov
- Restylane Kysse
- High for formulation, labelled area, pivotal-study outcomes, and safety; long-term response remains individual.
- FDA PMA P140029/S021 · accessdata.fda.gov
SourcesShowHide
Sources are grouped by treatment so the support for each record stays visible.
Juvéderm Voluma XC
- FDA PMA P110033/S070 · accessdata.fda.gov, 2023-10-06 · supports 2 fields
- Health Canada MDALL: Allergan Juvéderm licences · health-products.canada.ca
- Juvéderm Voluma XC Instructions for Use, P110033/S070 · accessdata.fda.gov, 2023-10-06 · supports 25 fields
- JUVÉDERM VOLUMA XC summary of safety and effectiveness · accessdata.fda.gov
Restylane Kysse
- FDA PMA P140029/S021 · accessdata.fda.gov, 2020-03-25 · supports 2 fields
- FDA Summary of Safety and Effectiveness Data P140029/S021 · accessdata.fda.gov, 2020-03-25
- Health Canada MDALL: Q-Med Restylane licences · health-products.canada.ca
- Restylane Kysse Instructions for Use · restylaneusa.com · supports 15 fields
- Restylane Kysse Patient Safety Information · restylaneusa.com · supports 8 fields
See average treatment prices near you
Enter a US ZIP code or Canadian postal code to check our stored estimate for the surrounding market.